Nasdaq

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Seeking Alpha

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...
Seeking Alpha

Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript

Good morning, and welcome to the Structure Therapeutics Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded. I would now like to turn the call over ...
Yahoo Finance

IVY Rx Claims Evaluated: 2026 Compounded GLP-1 Telehealth Program Details, Monthly Pricing Structure, Clinician Access Model, and Patient Eligibility Information

Miami, FL, April 10, 2026 (GLOBE NEWSWIRE)-- Affiliate Disclosure: This article contains affiliate links. If readers purchase through these links, a commission may be earned at no additional cost.